Repligen (NASDAQ:RGEN) Shares Up 5.4% – Here’s What Happened

Repligen Co. (NASDAQ:RGEN) shot up 5.4% during trading on Tuesday . The company traded as high as $144.49 and last traded at $144.38. 133,624 shares traded hands during trading, a decline of 79% from the average session volume of 637,420 shares. The stock had previously closed at $136.99.

Analyst Upgrades and Downgrades

A number of research firms recently commented on RGEN. Canaccord Genuity Group initiated coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Royal Bank of Canada boosted their price target on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. JPMorgan Chase & Co. raised their price objective on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Wolfe Research began coverage on shares of Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price target on shares of Repligen in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.00.

Repligen Stock Up 4.7 %

The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company has a market cap of $8.03 billion, a price-to-earnings ratio of -280.07, a PEG ratio of 4.54 and a beta of 0.95. The business has a 50-day simple moving average of $157.09 and a two-hundred day simple moving average of $148.51.

Repligen (NASDAQ:RGEN) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. As a group, equities analysts forecast that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD lifted its stake in Repligen by 11.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock valued at $1,027,165,000 after buying an additional 743,815 shares in the last quarter. Vanguard Group Inc. boosted its stake in Repligen by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company’s stock worth $734,251,000 after purchasing an additional 56,723 shares during the period. Champlain Investment Partners LLC increased its holdings in Repligen by 8.6% during the 4th quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company’s stock worth $222,176,000 after purchasing an additional 122,595 shares in the last quarter. Alliancebernstein L.P. raised its stake in shares of Repligen by 23.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company’s stock valued at $145,508,000 after purchasing an additional 191,439 shares during the period. Finally, Conestoga Capital Advisors LLC lifted its position in shares of Repligen by 0.7% in the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock worth $136,395,000 after purchasing an additional 6,872 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.